MedTrace Logo

Low Voltage Electrical Stimulation for Depression in Parkinson's Patients

NCT06467695 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-06

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the relative efficacy of fMRI model guided Transcranial Direct Current Stimulation (mgTDCS) in improving the depressive symptoms of patients with Parkinson's Disease (PD). The main questions it aims to answer are: 1) Can the use of mgTDCS significantly improve the self-reported level of depression and apathy in patients with PD from pre-intervention to post-intervention compared to a sham control? 2) Can the use of mgTDCS significantly normalize the cortical eeg alpha asymmetry so commonly seen in depressed patients compared to sham mgTDCS? 3) Can the use of mgTDCS significantly improve scores on neuropsychological tests of working memory?

Conditions

  • Parkinson Disease
  • Depressive Symptoms

Interventions

DEVICE

BIOPAC Stimsola

Transcranial Electrical Stimulator

DEVICE

BIOPAC Stimsola Sham (zero amps)

Transcranial Electrical Stimulator set to 0 amps

Sponsors & Collaborators

  • University of South Alabama

    lead OTHER

Principal Investigators

  • John Shelley-Tremblay, PhD · 2514606883

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2027-05-01
Completion
2027-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06467695 on ClinicalTrials.gov